Press release
13 Jan 2025  | London, GB

Smaller, smarter deals: Dealmaking volume stable but value is down as life sciences companies turn to innovative early-stage assets with China and AI becoming major sources of innovation

  • Dealmaking volume is stable, but value fell 41% to US$130b as companies pivot to smaller, smarter deals
  • Leading bio-pharma companies still hold significant levels of Firepower, US$1.3t going into 2025, and confronts a US$240b growth gap by 2030
  • 65% of all big pharma revenues now come from dealmaking, confirming a need for robust inorganic growth and value creation strategies

The global life sciences industry has pivoted from major dealmaking to smaller, smarter and more agile deals with mergers and acquisitions (M&A) investment totaling US$130b in 2024, a 41% decrease compared with US$222b in 2023, as the industry turned away from the big deals for de-risked assets that characterized 2023. Though deal value is down, volume is stable (with biopharma deals +17% vs. 2023), but average deal size dropped, as companies shifted focus to look for earlier-stage opportunities with lower price tags, according to the report (Report).

According to the 12th edition of the annual EY M&A Firepower report, which tracks global M&A investment in life sciences, instead of investing multibillions to acquire de-risked, market-ready assets, 51% of 2024 biopharma deals targeted earlier-stage (pre-Phase III) assets, trying to tap innovation at an earlier point in the development cycle. The slow pace of activity in 2024 may have resulted from the ongoing regulatory challenges from the pro-active Federal Trade Commission (FTC) and the ongoing implementation of the Inflation Reduction Act (IRA) in the US, and as a natural “reset” after the heightened activity of the previous year.

The life sciences AI opportunity

According to the EY Report, a surge in life sciences artificial intelligence (AI) partnerships highlights the opportunities the technology offers to life sciences companies, resulting in over US$55b in potential deal value, spread over more than 330 deals in the past five years. Recursion Pharmaceuticals completed the largest life sciences AI M&A deal to date in August 2024, acquiring Exscientia for US$712m and most leading life sciences companies have now established one or more AI partnership. AI seems to offer gains across the value chain from operations to commercial strategy. However, the Report details three challenges the industry will face to successfully partner with these technology companies: finding the right data strategy, learning to use AI end-to-end, and getting education and integration strategies in place across the firm.

China: widening the search for innovation value

As life sciences companies widen the search for new value drivers beyond the traditional fields of innovation, the EY M&A Firepower report reveals China is becoming an increasingly important research and development (R&D) target for companies seeking to license-in antibody-drug conjugates (ADCs) and other novel oncology treatments. The first-ever full buyout of an innovative Chinese biotech by a big pharma saw AstraZeneca pay US$1.2b to acquire Gracell Biotechnologies Inc in 2024. Additionally, one of the US biggest potential value biobucks deals (potential milestone payments if the alliance meets its clinical and commercial goals) of 2024 was Novartis/Shanghai Argo Biopharmaceutical Co Ltd ($4.2b). The report also notes that approximately 85% of China out-licensing deals are focused on oncology. However, challenges to the growth of China’s life sciences innovation economy include the US BIOSECURE Act, due to take effect in 2032 and the uncertainties of the China-US relationship under the incoming US administration.

2025 dealmaking

The EY M&A Firepower report reveals there are strong structural reasons to expect a return to dealmaking; the industry is still holding US$1.3 trillion in dealmaking Firepower, meaning dry powder is there to make bigger deals – though the Firepower is unevenly distributed, with Novo Nordisk and Eli Lilly dominating. The industry also faces upcoming revenue challenges, with patent expiries set to wipe out US$300 billion in revenues by 2028, and growth gaps of US$240 billion looming by 2030. Additionally, the incoming administration in the US may offer significant tailwinds to the industry in the form of in corporate tax rate cuts and a potential roll-back of the IRA’s drug pricing provisions and the FTC’s interventionist stance, as part of a general deregulatory shift. However, despite these drivers, the Report found potential restraints to the 2025 market; the reduced number of high-quality de-risked assets, the ongoing margin pressure on life sciences companies reducing appetite for big spending and the fact that the most prized targets are still commanding high premiums in the market (a median of 75% in 2024, well above historical norms). 

Subin Baral, EY Global Life Sciences Deals Leader, says:

“For large pharmaceutical companies, 2024 may have been a ‘digestion year,’ as they integrate the acquisitions made the previous year. At the same time, the appetite for M&A remains strong, with biopharma companies signing more deals in 2024 than the previous year.”

“Companies have focused on smart, bolt-on moves, looking for value in less obvious places. That strategic mindset will continue into 2025, though there is also growing optimism around the business environment in the coming year, which could see the industry unleash more of its US$1.3 trillion Firepower. With nearly two-thirds of all major pharma company revenues set to come from dealmaking in the next five years, deals will remain at the center of life sciences strategy.”

Looking ahead to 2025:

  1. Deals will continue at the center of life sciences strategy, and companies need a robust partnering approach to shape their future with confidence.
  2. Smaller, smarter deals offer strong potential returns on investment for companies with the agility to tap these strategic opportunities.
  3. Therapeutic area focus will remain a key priority in dealmaking, and we expect portfolio prioritization to continue with companies divesting non-core assets and investing in priority areas.
  4. Opportunities outside traditional technological and geographical areas of innovation – such as AI startups and China biotech – offer an accelerated route to growth.
  5. Across all dealmaking strategies, end-to-end execution is critical to realizing a strong return on investment, with culture and change experience at the center of execution strategies.

The full EY report is available at ey.com/firepower.

-ends-

Notes to editors

About EY

EY is building a better working world by creating new value for clients, people, society and the planet, while building trust in capital markets.

Enabled by data, AI and advanced technology, EY teams help clients shape the future with confidence and develop answers for the most pressing issues of today and tomorrow. 

EY teams work across a full spectrum of services in assurance, consulting, tax, strategy and transactions. Fueled by sector insights, a globally connected, multi-disciplinary network and diverse ecosystem partners, EY teams can provide services in more than 150 countries and territories.

All in to shape the future with confidence. 

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

This news release has been issued by EYGM Limited, a member of the global EY organization that also does not provide any services to clients.

About the EY M&A Firepower report

Now in its 12th year, the EY M&A Firepower report measures companies’ capacity to fund transactions based on the strength of their balance sheets. It has four key inputs: 1. cash and equivalents; 2. existing debt; 3. debt capacity, including credit lines; and 4. market capitalization. In constructing the model, the following assumptions were made: first, a company will not acquire targets that exceed 50% of its existing market capitalization; second, the debt/equity ratio of the combined entity created by a transaction cannot exceed 30%.

While some life sciences companies have made acquisitions that go beyond these upper limits, the intent is to apply a uniform methodology to measure relative changes in Firepower. The EY Firepower report measures capacity to conduct M&A transactions financed with cash or debt. It does not measure the ability to conduct stock-for-stock transactions. However, increases in a company’s stock price do boost its Firepower under the EY Firepower report’s formula, largely because equity enables companies to borrow more to finance transactions.

About EY Health Sciences and Wellness

The rise of the empowered consumer, coupled with technology advancements and the emergence of digitally focused entrants, is changing every aspect of health and care delivery. To retain relevancy in today’s digitally focused, data-infused ecosystem, all participants in health care today must rethink their business practices, including capital strategy, partnering and the creation of patient-centric operating models.

The EY Health Sciences and Wellness architecture brings together a worldwide network of 34,000 professionals to build data-centric approaches to customer engagement and improved outcomes. We help our clients deliver on their strategic goals; design optimized operating models; and form the right partnerships so they may thrive today and succeed in the health systems of tomorrow. We work across the ecosystem to understand the implications of today’s trends, proactively finding solutions to business issues and to seize the upside of disruption in this transformative age.

Related news